Daniel F Ortwine Selected Research

emt protein-tyrosine kinase (IL2-inducible T-cell kinase)

12/2016	Fragment Molecular Orbital Method Applied to Lead Optimization of Novel Interleukin-2 Inducible T-Cell Kinase (ITK) Inhibitors.
5/2015	Tetrahydroindazoles as Interleukin-2 Inducible T-Cell Kinase Inhibitors. Part II. Second-Generation Analogues with Enhanced Potency, Selectivity, and Pharmacodynamic Modulation in Vivo.
7/2014	Property- and structure-guided discovery of a tetrahydroindazole series of interleukin-2 inducible T-cell kinase inhibitors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Daniel F Ortwine Research Topics

Disease

6	Neoplasms (Cancer) 10/2016 - 08/2006
5	Asthma (Bronchial Asthma) 12/2016 - 12/2013
2	Breast Neoplasms (Breast Cancer) 10/2021 - 01/2021
2	Pain (Aches) 01/2019 - 01/2018
2	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/2018 - 06/2017
2	Arthritis (Polyarthritis) 01/2018 - 09/2007
2	Rheumatoid Arthritis 01/2018 - 06/2017
2	Osteoarthritis 02/2008 - 09/2007
1	autosomal dominant Spastic paraplegia 6 01/2019
1	Chronic Pain 01/2019
1	Autoimmune Diseases (Autoimmune Disease) 01/2018
1	B-Cell Lymphoma (Lymphoma, B Cell) 06/2017
1	Neuroblastoma 09/2013
1	Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder) 02/2010
1	Carcinoma (Carcinomatosis) 10/2007

Drug/Important Bio-Agent (IBA)

4	T-Cell Antigen Receptors (T-Cell Receptor)IBA 05/2015 - 12/2013
3	emt protein-tyrosine kinase (IL2-inducible T-cell kinase)IBA 12/2016 - 07/2014
2	SulfonamidesIBA 01/2019 - 01/2018
2	Agammaglobulinaemia Tyrosine KinaseIBA 06/2017 - 10/2016
2	Interleukin-2 (IL2)IBA 05/2015 - 07/2014
2	Phosphotransferases (Kinase)IBA 07/2014 - 08/2006
2	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 06/2014 - 12/2013
2	ZincIBA 09/2013 - 09/2007
1	Estrogen ReceptorsIBA 10/2021
1	Estrogen Receptor AntagonistsIBA 01/2021
1	giredestrantIBA 01/2021
1	LigandsIBA 01/2019
1	fenebrutinibIBA 01/2018
1	Sodium Channels (Sodium Channel)IBA 01/2018
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 12/2016
1	ibrutinibIBA 10/2016
1	Tyrosine (L-Tyrosine)FDA Link 07/2014
1	Histones (Histone)IBA 09/2013
1	Hydroxamic Acids (Hydroxamic Acid)IBA 09/2013
1	BenzamidesIBA 09/2013
1	Histone Deacetylase InhibitorsIBA 09/2013
1	Histone Deacetylases (Histone Deacetylase)IBA 09/2013
1	Protein Kinases (Protein Kinase)IBA 01/2013
1	GDC-0349IBA 01/2013
1	Mechanistic Target of Rapamycin Complex 1IBA 12/2012
1	Mechanistic Target of Rapamycin Complex 2IBA 12/2012
1	HhAntag691IBA 04/2011
1	Norepinephrine (Noradrenaline)FDA LinkGeneric 02/2010
1	Matrix Metalloproteinase 13IBA 02/2008
1	QuinazolinonesIBA 02/2008
1	EnzymesIBA 10/2007
1	2- (2- chloro- 4- iodophenylamino)- N- cyclopropylmethoxy- 3,4- difluorobenzamideIBA 10/2007
1	Matrix Metalloproteinase InhibitorsIBA 09/2007
1	Pharmaceutical PreparationsIBA 09/2007
1	Peptide Hydrolases (Proteases)FDA Link 09/2007

Therapy/Procedure

2	Therapeutics 01/2018 - 09/2013
1	Drug Therapy (Chemotherapy) 08/2006